摘要：本文首先根据GenBank上公布的小鼠UCP1基因的DNA序列，截取基因组序列中包括第一外显子在内的约2300bp(翻译起始点上游-2000bp至下游200bp)的UCP1基因5’调控区序列，然后利用Neuralnetworkpromoterprediction、Consite、EMBOSSCpgplot、MethPrimer等生物信息学分析软件初步确定UCP1基因的核心启动子区域，并进一步对该区域潜在转录因子的结合位点和CpG岛进行预测。结果显示，将得分门槛设置为0.8时预测到了两条核心启动子序列；该5’调控区存在多个转录因子结合位点：将评分设置为90％时，存在12个潜在转录因子的结合位点；评分设置为95％时,存在4个潜在转录因子结合位点；评分设置为100％时，仍存在2个潜在转录因子结合位点;CpG岛在1394bp~1499bp区间内，长度为106bp。对小鼠UCP1基因启动子的生物信息学分析为基于褐色脂肪组织的肥胖治疗提供了理论依据。

关键词：UCP1；调控区；启动子；转录因子；生物信息学分析

Bioinformatics Analysis of Mouse UCP1 Gene Promoter

Abstract：Based on the DNA sequence of mouse UCP1 gene published in GenBank, the 5 'regulatory region of UCP1 gene in 2300bp (-2000bp to 200bp upstream) including the first exon was inserted into the genome sequence. The core promoter region of UCP1 gene was preliminarily determined by biofilter analysis software such as Neural network promoter prediction, Consite, EMBOSS Cpgplot and MethPrimer, and the binding site of potential transcription factor and CpG island were predicted. The results showed that two core promoter sequences were predicted when the scoring threshold was set to 0.8; there were multiple transcription factor binding sites in the 5 'regulatory region: when the score was set to 90%, there were 12 potential transcription factors And there were four potential transcription factor binding sites when the score was set to 95%. When the score was set to 100%, there were two potential transcription factor binding sites. The CpG island had a length of 106bp in the range of 1394bp ~ 1499bp.The bioinformatics analysis of mouse UCP1 gene promoter provides a theoretical basis for obesity treatment based on brown adipose tissue.

Key Words：UCP1；regulatory region；Promoter；Transcription factors；Bioinformatics Analysis

目录

摘要 1

引言 2

1．材料与方法 3

1.1材料 3

1.2方法 3

1.2.1UCP1基因5’调控区序列的获得 3

1.2.2预测启动子核心序列 3

1.2.3预测转录因子结合位点 3

1.2.4CpG岛的预测 4

2.结果与分析 4

2.1UCP1基因5’调控区序列的获得 4

2.2核心启动子区的预测 5

2.3Consite系统预测UCP1基因5’调控区序列中可能的转录因子的结合位点 6

2.4CpG岛预测 7

3.讨论与结论 9

参考文献 10

致谢 12

小鼠UCP1基因启动子的生物信息学分析

引言

如今，肥胖症使全人类的健康面临着严重的威胁[1]，经研究，人和动物的肥胖都跟环境、饮食和基因等众多因素有关，其中基因是主要的决定性因素，所以药物治疗受到很大的限制。随着肥胖症的日益普遍化，人类需尽快开发出治疗肥胖症的新方法[2]。由于能量消耗对肥胖症的治疗极富吸引力，所以以生物能量学为途径治疗肥胖症可能是目前最有效的方法[3]。而解偶联蛋白家族的发现就为人类研究肥胖机制开辟了新途径。

解偶联蛋白家族（uncouplingproteins,UCPs）是分布在线粒体内膜上具有解离氧化磷酸化偶联功能的转运蛋白，对机体能量平衡涉及的肥胖、静止代谢率和食物转化效率等性状具有显著的影响[4]。解偶联蛋白中的UCP1是最早发现的，并且唯一在褐色脂肪组织（brownadiposetissue,BAT）中表达的解偶联蛋白质，大量存在于褐色脂肪组织的线粒体内膜上[5-7]，具有显著的抗肥胖功能，这使得棕色脂肪组织成为当前研究肥胖和脂代谢的热点。